secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001104659-25-048915
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma Q1 net income $21.5M on warrant gain; cash $15.9M; CEO transition
------------------------------------------------------------------------------

- Net income of $21.5M ($2.17 basic EPS) driven by $26.5M gain from warrant liability fair value change; revenue $57K.
- Cash and equivalents $15.9M as of Mar 31, 2025, down from $21.3M; runway into Q1 2026.
- Submitted FDA briefing package for tivoxavir marboxil (TXM) under Animal Rule; ratutrelvir briefing package planned Q2 2025.
- Iain Dukes named Interim CEO after retirement of Werner Cautreels; Jack Stover appointed Chairman.
- R&D expense $2.5M (+$0.6M YoY) on virology program; G&A $2.8M (-$0.6M YoY) on lower consulting fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925048915/0001104659-25-048915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925048915/tm2515069d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-048915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer